Global Recombinant Human Interleukin-11 for Injection 麻豆原创 Research Report 2024

Publication ID:

PB504244086

Publication Date:

April 23, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Recombinant Human Interleukin-11 for Injection is a drug used to increase the number of blood cells, especially platelets, in some cancer patients receiving chemotherapy. Recombinant human interleukin-11 is a form of interleukin-11 (a cytokine normally made by support cells in the bone marrow) that is made in the laboratory. It is a type of biological response modifier. Also called Neumega, oprelvekin, and rhIL-11.
The global Recombinant Human Interleukin-11 for Injection market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Recombinant Human Interleukin-11 for Injection is a biopharmaceutical with vast market potential in the medical sector. The market size is continuously expanding, driven primarily by its effectiveness in treating chemotherapy-induced thrombocytopenia in malignancies and its potential applications in diseases like enteritis, enteric viral infections, and ulcerative colitis. Additionally, it plays a crucial role in bone marrow suppression, bone marrow transplantation, and post-radiotherapy recovery. Due to its broad scope of applications, sales have been steadily increasing, and future developments may involve approvals for additional indications and the adoption of new manufacturing technologies to enhance production efficiency and drug accessibility.
This report aims to provide a comprehensive presentation of the global market for Recombinant Human Interleukin-11 for Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Human Interleukin-11 for Injection.
Report Scope
The Recombinant Human Interleukin-11 for Injection market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Human Interleukin-11 for Injection market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Human Interleukin-11 for Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Xiamen Amoytop Biotech
SL Pharm
Qilu Pharmaceutical
Angde Biotech Pharmaceutical
Hangzhou Jiuyuan Gene Engineering
Segment by Type
1mg
1.5mg
3mg
5mg
Other
Segment by Application
Hospital
Pharmacy
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Human Interleukin-11 for Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Human Interleukin-11 for Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Recombinant Human Interleukin-11 for Injection 麻豆原创 Overview
1.1 Product Overview and Scope of Recombinant Human Interleukin-11 for Injection
1.2 Recombinant Human Interleukin-11 for Injection Segment by Type
1.2.1 Global Recombinant Human Interleukin-11 for Injection 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 1mg
1.2.3 1.5mg
1.2.4 3mg
1.2.5 5mg
1.2.6 Other
1.3 Recombinant Human Interleukin-11 for Injection Segment by Application
1.3.1 Global Recombinant Human Interleukin-11 for Injection 麻豆原创 Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Pharmacy
1.4 Global Recombinant Human Interleukin-11 for Injection 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Recombinant Human Interleukin-11 for Injection Revenue 2019-2030
1.4.2 Global Recombinant Human Interleukin-11 for Injection Sales 2019-2030
1.4.3 Global Recombinant Human Interleukin-11 for Injection 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Recombinant Human Interleukin-11 for Injection 麻豆原创 Competition by Manufacturers
2.1 Global Recombinant Human Interleukin-11 for Injection Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Recombinant Human Interleukin-11 for Injection Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Recombinant Human Interleukin-11 for Injection Average Price by Manufacturers (2019-2024)
2.4 Global Recombinant Human Interleukin-11 for Injection Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Recombinant Human Interleukin-11 for Injection, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant Human Interleukin-11 for Injection, Product Type & Application
2.7 Recombinant Human Interleukin-11 for Injection 麻豆原创 Competitive Situation and Trends
2.7.1 Recombinant Human Interleukin-11 for Injection 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Recombinant Human Interleukin-11 for Injection Players 麻豆原创 Share by Revenue
2.7.3 Global Recombinant Human Interleukin-11 for Injection 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Recombinant Human Interleukin-11 for Injection Retrospective 麻豆原创 Scenario by Region
3.1 Global Recombinant Human Interleukin-11 for Injection 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Recombinant Human Interleukin-11 for Injection Global Recombinant Human Interleukin-11 for Injection Sales by Region: 2019-2030
3.2.1 Global Recombinant Human Interleukin-11 for Injection Sales by Region: 2019-2024
3.2.2 Global Recombinant Human Interleukin-11 for Injection Sales by Region: 2025-2030
3.3 Global Recombinant Human Interleukin-11 for Injection Global Recombinant Human Interleukin-11 for Injection Revenue by Region: 2019-2030
3.3.1 Global Recombinant Human Interleukin-11 for Injection Revenue by Region: 2019-2024
3.3.2 Global Recombinant Human Interleukin-11 for Injection Revenue by Region: 2025-2030
3.4 North America Recombinant Human Interleukin-11 for Injection 麻豆原创 Facts & Figures by Country
3.4.1 North America Recombinant Human Interleukin-11 for Injection 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Recombinant Human Interleukin-11 for Injection Sales by Country (2019-2030)
3.4.3 North America Recombinant Human Interleukin-11 for Injection Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Recombinant Human Interleukin-11 for Injection 麻豆原创 Facts & Figures by Country
3.5.1 Europe Recombinant Human Interleukin-11 for Injection 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Recombinant Human Interleukin-11 for Injection Sales by Country (2019-2030)
3.5.3 Europe Recombinant Human Interleukin-11 for Injection Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant Human Interleukin-11 for Injection 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Recombinant Human Interleukin-11 for Injection 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Recombinant Human Interleukin-11 for Injection Sales by Country (2019-2030)
3.6.3 Asia Pacific Recombinant Human Interleukin-11 for Injection Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Recombinant Human Interleukin-11 for Injection 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Recombinant Human Interleukin-11 for Injection 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Recombinant Human Interleukin-11 for Injection Sales by Country (2019-2030)
3.7.3 Latin America Recombinant Human Interleukin-11 for Injection Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Recombinant Human Interleukin-11 for Injection 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant Human Interleukin-11 for Injection 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Recombinant Human Interleukin-11 for Injection Sales by Country (2019-2030)
3.8.3 Middle East and Africa Recombinant Human Interleukin-11 for Injection Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Recombinant Human Interleukin-11 for Injection Sales by Type (2019-2030)
4.1.1 Global Recombinant Human Interleukin-11 for Injection Sales by Type (2019-2024)
4.1.2 Global Recombinant Human Interleukin-11 for Injection Sales by Type (2025-2030)
4.1.3 Global Recombinant Human Interleukin-11 for Injection Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Recombinant Human Interleukin-11 for Injection Revenue by Type (2019-2030)
4.2.1 Global Recombinant Human Interleukin-11 for Injection Revenue by Type (2019-2024)
4.2.2 Global Recombinant Human Interleukin-11 for Injection Revenue by Type (2025-2030)
4.2.3 Global Recombinant Human Interleukin-11 for Injection Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Recombinant Human Interleukin-11 for Injection Price by Type (2019-2030)
5 Segment by Application
5.1 Global Recombinant Human Interleukin-11 for Injection Sales by Application (2019-2030)
5.1.1 Global Recombinant Human Interleukin-11 for Injection Sales by Application (2019-2024)
5.1.2 Global Recombinant Human Interleukin-11 for Injection Sales by Application (2025-2030)
5.1.3 Global Recombinant Human Interleukin-11 for Injection Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Recombinant Human Interleukin-11 for Injection Revenue by Application (2019-2030)
5.2.1 Global Recombinant Human Interleukin-11 for Injection Revenue by Application (2019-2024)
5.2.2 Global Recombinant Human Interleukin-11 for Injection Revenue by Application (2025-2030)
5.2.3 Global Recombinant Human Interleukin-11 for Injection Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Recombinant Human Interleukin-11 for Injection Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Xiamen Amoytop Biotech
6.1.1 Xiamen Amoytop Biotech Corporation Information
6.1.2 Xiamen Amoytop Biotech Description and Business Overview
6.1.3 Xiamen Amoytop Biotech Recombinant Human Interleukin-11 for Injection Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Xiamen Amoytop Biotech Recombinant Human Interleukin-11 for Injection Product Portfolio
6.1.5 Xiamen Amoytop Biotech Recent Developments/Updates
6.2 SL Pharm
6.2.1 SL Pharm Corporation Information
6.2.2 SL Pharm Description and Business Overview
6.2.3 SL Pharm Recombinant Human Interleukin-11 for Injection Sales, Revenue and Gross Margin (2019-2024)
6.2.4 SL Pharm Recombinant Human Interleukin-11 for Injection Product Portfolio
6.2.5 SL Pharm Recent Developments/Updates
6.3 Qilu Pharmaceutical
6.3.1 Qilu Pharmaceutical Corporation Information
6.3.2 Qilu Pharmaceutical Description and Business Overview
6.3.3 Qilu Pharmaceutical Recombinant Human Interleukin-11 for Injection Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Qilu Pharmaceutical Recombinant Human Interleukin-11 for Injection Product Portfolio
6.3.5 Qilu Pharmaceutical Recent Developments/Updates
6.4 Angde Biotech Pharmaceutical
6.4.1 Angde Biotech Pharmaceutical Corporation Information
6.4.2 Angde Biotech Pharmaceutical Description and Business Overview
6.4.3 Angde Biotech Pharmaceutical Recombinant Human Interleukin-11 for Injection Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Angde Biotech Pharmaceutical Recombinant Human Interleukin-11 for Injection Product Portfolio
6.4.5 Angde Biotech Pharmaceutical Recent Developments/Updates
6.5 Hangzhou Jiuyuan Gene Engineering
6.5.1 Hangzhou Jiuyuan Gene Engineering Corporation Information
6.5.2 Hangzhou Jiuyuan Gene Engineering Description and Business Overview
6.5.3 Hangzhou Jiuyuan Gene Engineering Recombinant Human Interleukin-11 for Injection Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Hangzhou Jiuyuan Gene Engineering Recombinant Human Interleukin-11 for Injection Product Portfolio
6.5.5 Hangzhou Jiuyuan Gene Engineering Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant Human Interleukin-11 for Injection Industry Chain Analysis
7.2 Recombinant Human Interleukin-11 for Injection Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant Human Interleukin-11 for Injection Production Mode & Process
7.4 Recombinant Human Interleukin-11 for Injection Sales and 麻豆原创ing
7.4.1 Recombinant Human Interleukin-11 for Injection Sales Channels
7.4.2 Recombinant Human Interleukin-11 for Injection Distributors
7.5 Recombinant Human Interleukin-11 for Injection Customers
8 Recombinant Human Interleukin-11 for Injection 麻豆原创 Dynamics
8.1 Recombinant Human Interleukin-11 for Injection Industry Trends
8.2 Recombinant Human Interleukin-11 for Injection 麻豆原创 Drivers
8.3 Recombinant Human Interleukin-11 for Injection 麻豆原创 Challenges
8.4 Recombinant Human Interleukin-11 for Injection 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Xiamen Amoytop Biotech
SL Pharm
Qilu Pharmaceutical
Angde Biotech Pharmaceutical
Hangzhou Jiuyuan Gene Engineering

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.